Compile Data Set for Download or QSAR
Report error Found 1636 of affinity data for UniProtKB/TrEMBL: Q7Z5P4
Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714833(4-((5-(2,4-difluoro-3- hydroxyphenyl)-1,3,4-thiadi...)
Affinity DataIC50: 0.790nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714793(US20250026745, Compound I-54A)
Affinity DataIC50: 0.857nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM50632087(CHEMBL5417980)
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant human full-length C-terminal His-tagged HSD17B13 using estradiol and NAD as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/22/2024
Entry Details
PubMed
Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM50632088(CHEMBL5411903)
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant human full-length C-terminal His-tagged HSD17B13 using estradiol and NAD as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/22/2024
Entry Details
PubMed
Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM50632089(CHEMBL5307400)
Affinity DataIC50: 1nMAssay Description:Uncompetitive inhibition of recombinant human full-length C-terminal His-tagged HSD17B13 using estradiol and NAD as substrate preincubated for 10 min...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/22/2024
Entry Details
PubMed
Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714825((R)-4-((5-(2,4-difluoro-3- hydroxyphenyl)-1,3,4-th...)
Affinity DataIC50: 1.01nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714790((S)-4-((5-(2-chloro-4-fluoro-3- hydroxyphenyl)-1,3...)
Affinity DataIC50: 1.09nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714834((S)-4-((5-(2,4-difluoro-3- hydroxyphenyl)-1,3,4-th...)
Affinity DataIC50: 1.17nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714792(4-((5-(2-chloro-4-fluoro-3- hydroxyphenyl)-1,3,4-t...)
Affinity DataIC50: 1.53nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714817((R)-4-((5-(2,4-difluoro-3- hydroxyphenyl)-1,3,4-th...)
Affinity DataIC50: 1.76nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714818((S)-4-((5-(2,4-difluoro-3- hydroxyphenyl)-1,3,4-th...)
Affinity DataIC50: 2nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714795(6-benzyl-4-((5-(2-fluoro-3-hydroxy- 5-(trifluorome...)
Affinity DataIC50: 2.14nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714759(6-benzyl-4-((5-(2,4-difluoro-3- hydroxyphenyl)-1,3...)
Affinity DataIC50: 2.28nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714797(6-benzyl-4-((5-(2,4-difluoro-3- hydroxy-5-(trifluo...)
Affinity DataIC50: 2.46nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714821(4-((5-(2,4-difluoro-3- hydroxyphenyl)-1,3,4-thiadi...)
Affinity DataIC50: 2.5nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM674206(N-({(1r,4r)-4-[6- (1-tert-butyl-1H- pyrazol-4-yl)-...)
Affinity DataIC50: 2.60nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714770((R)-4-((5-(2-chloro-4-fluoro-3- hydroxyphenyl)-1,3...)
Affinity DataIC50: 2.68nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM674198(2,3,5-trifluoro-4-hydroxy-N- ({(1r,4r)-4-[6- (pyri...)
Affinity DataIC50: 2.70nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM674205(N-({(1r,4r)-4-[6-(3-cyclopropyl- 1-methyl-1H- pyra...)
Affinity DataIC50: 2.80nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM50632077(CHEMBL5418605)
Affinity DataIC50: 3nMAssay Description:Inhibition of recombinant human full-length C-terminal His-tagged HSD17B13 using estradiol and NAD as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/22/2024
Entry Details
PubMed
Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM50632085(CHEMBL5405782)
Affinity DataIC50: 3nMAssay Description:Inhibition of recombinant human full-length C-terminal His-tagged HSD17B13 using estradiol and NAD as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/22/2024
Entry Details
PubMed
Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM50632088(CHEMBL5411903)
Affinity DataIC50: 3nMAssay Description:Inhibition of recombinant human full-length C-terminal His-tagged HSD17B13 expressed in HEK293 cells using estradiol as substrate preincubated for 30...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/22/2024
Entry Details
PubMed
Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714832(6-(1-(3,4'-difluoro-[1,1'-biphenyl]- 4-yl)-2,2,2-t...)
Affinity DataIC50: 3.11nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM674210(3,5-difluoro-4- hydroxy-N- {[(1r,4r)-4-{6-[1- (pro...)
Affinity DataIC50: 3.20nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714807(6-benzyl-4-((5-(2,4,5-trifluoro-3- hydroxyphenyl)-...)
Affinity DataIC50: 3.23nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM674211(3,5-difluoro-4- hydroxy-N- ({(1r,4r)-4-[6-(1- meth...)
Affinity DataIC50: 3.40nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM674279(3,5-difluoro-4- hydroxy-N- ({(1r,4r)-4-[6-(1,3- th...)
Affinity DataIC50: 3.70nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714771((S)-4-((5-(2-chloro-4-fluoro-3- hydroxyphenyl)-1,3...)
Affinity DataIC50: 3.72nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM674218(N-({(1r,4r)-4-[6- (5,6-dihydro- 4H-pyrrolo[1,2-b] ...)
Affinity DataIC50: 3.80nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM674232(3,5-difluoro-4- hydroxy-N-({(1r,4r)-4- [6-(1-methy...)
Affinity DataIC50: 3.80nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM50632076(CHEMBL5405439)
Affinity DataIC50: 4nMAssay Description:Inhibition of recombinant human full-length C-terminal His-tagged HSD17B13 using estradiol and NAD as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/22/2024
Entry Details
PubMed
Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM50632078(CHEMBL5429503)
Affinity DataIC50: 4nMAssay Description:Inhibition of recombinant human full-length C-terminal His-tagged HSD17B13 using estradiol and NAD as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/22/2024
Entry Details
PubMed
Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM50632084(CHEMBL5423975)
Affinity DataIC50: 4nMAssay Description:Inhibition of recombinant human full-length C-terminal His-tagged HSD17B13 using estradiol and NAD as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/22/2024
Entry Details
PubMed
Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714827((S)-4-((5-(4-fluoro-3-hydroxy-2- methylphenyl)-1,3...)
Affinity DataIC50: 4nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714819(6-(tert-butyl)-4-((5-(2,4-difluoro-3- hydroxypheny...)
Affinity DataIC50: 4.07nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714781((R)-6-(sec-butyl)-4-((5-(2,4- difluoro-3-hydroxyph...)
Affinity DataIC50: 4.08nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714780((S)-6-(sec-butyl)-4-((5-(2,4- difluoro-3-hydroxyph...)
Affinity DataIC50: 4.15nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM674196(N-{[(1r,4r)-4-(6- chloro-2H- indazol-2- yl)cylohex...)
Affinity DataIC50: 4.30nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM674202(N-({(1r,4r)-4-[5- (cyclopropyl-methoxy)-2H- pyrazo...)
Affinity DataIC50: 4.30nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714835(4-((5-(2-chloro-4-fluoro-3- hydroxyphenyl)-1,3,4-t...)
Affinity DataIC50: 4.39nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM674209(N-({(1r,4r)-4-[6- (1,5-dimethyl- 1H-pyrazol-4-yl)-...)
Affinity DataIC50: 4.40nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM674215(3,5-difluoro-4- hydroxy-N- {[(1r,4r)-4-{6-[1- (oxe...)
Affinity DataIC50: 4.40nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM674200(2,3,5-trifluoro-4-hydroxy-N- ({(1r,4r)-4-[6-(1- me...)
Affinity DataIC50: 4.60nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714773(4-((5-(2-chloro-4-fluoro-3- hydroxyphenyl)-1,3,4-t...)
Affinity DataIC50: 4.60nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM714789(6-(tert-butyl)-4-((5-(2-chloro-4- fluoro-3-hydroxy...)
Affinity DataIC50: 4.60nMAssay Description:More specifically, recombinant 17β-HSD13 protein was assayed in a buffer containing 200 mM Tris pH 7.5, 0.01% Triton X-100, and 0.02% BSA into a 384-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/30/2025
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM674223(3,5-difluoro-4- hydroxy-N- ({(1r,4r)-4-[6-(4- meth...)
Affinity DataIC50: 4.80nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM674266(3,5-difluoro-4- hydroxy-N-({(1r,4r)- [6-(1,3-thiaz...)
Affinity DataIC50: 4.80nMAssay Description:HSD17B13 uses the oxidized form of nicotinamide adenine dinucleotide (NAD+) as a cofactor during metabolism of beta-estradiol (substrate), converting...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2024
Entry Details
Go to US Patent

Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM50632079(CHEMBL5414092)
Affinity DataIC50: 5nMAssay Description:Inhibition of recombinant human full-length C-terminal His-tagged HSD17B13 using estradiol and NAD as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/22/2024
Entry Details
PubMed
Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM50632086(CHEMBL5394877)
Affinity DataIC50: 5nMAssay Description:Inhibition of recombinant human full-length C-terminal His-tagged HSD17B13 using estradiol and NAD as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/22/2024
Entry Details
PubMed
Target17-beta-hydroxysteroid dehydrogenase 13(Human)
Bluejay Therapeutics

US Patent
LigandPNGBDBM50632087(CHEMBL5417980)
Affinity DataIC50: 5nMAssay Description:Inhibition of recombinant human full-length C-terminal His-tagged HSD17B13 expressed in HEK293 cells using estradiol as substrate preincubated for 30...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/22/2024
Entry Details
PubMed
Displayed 1 to 50 (of 1636 total ) | Next | Last >>
Jump to: